This is a non-ticketed session.

Osteonecrosis of the jaws secondary to bisphosphonates emerged as new disease process in late 2003. Bisphosphonates were the first category of medications that were linked to osteonecrosis. In 2015, AAOMS revised its white paper on osteonecrosis of the jaws to include RANK-L inhibitors and updated staging and management. This symposium will discuss concepts in the pathophysiology, updates in management and treatment strategies for patients with osteonecrosis. Additionally, treatment strategies for patients taking oral bisphosphonate medication and who need oral surgical procedures will be discussed.

1. Identify the issues involved in treating patients who are taking bisphosphonates;
2. Describe the pathophysiology of bone necrosis and bone healing physiology; and
3. Evaluate the management modalities for the wide range of problems that may present with MRONJ.